Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,862 matching trials from the live ClinicalTrials.gov search.

Filters: Chapel Hill, North Carolina Clear all

Conditions: Asthma (Diagnosis), Persistent Asthma, Moderate Asthma Exacerbation
Interventions: Anakinra 100 Mg/0.67 Ml Inj Syringe, Saline Placebo/0.67 Ml Inj Syringe; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Lung Cancer
Interventions: mPATH-Lung, Lung health video; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 77 Years
Enrollment: 26,998 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Cystic Fibrosis
Interventions: PFP; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Rett Syndrome
Interventions: Trofinetide, Placebo; Drug · Other
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 5 Years to 20 Years · Female only
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more

Conditions: Chronic Idiopathic Constipation
Interventions: SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg, SP-304 9.0 mg, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 14
States / cities: Mesa, Arizona • Tucson, Arizona • Anaheim, California + 11 more

Conditions: Frailty, Weakness, Muscle, Multiple Chronic Conditions
Interventions: Beta-hydroxymethyl butyrate supplement, Vitamin D supplement, Matching Beta-hydroxymethyl butyrate supplement without Vitamin D; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 65 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Interventions: Not listed
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 7,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 65
States / cities: Phoenix, Arizona • Palo Alto, California • Pasadena, California + 51 more

Conditions: Metastatic Urothelial Cancer
Interventions: Olaparib; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 7
States / cities: Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 4 more

Conditions: Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions: CD34-positive cells, Saline and 5% autologous plasma; Biological
Lead sponsor: Losordo, Douglas, M.D.; Individual
Eligibility: 21 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 12
States / cities: Birmingham, Alabama • Gainsville, Florida • Orlando, Florida + 9 more

Conditions: Social Isolation, Loneliness
Interventions: Experimental Health Communication, Simulated Social Media Platform Only; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 29 Years
Enrollment: 1,900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Prospective study assessments; Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more

Conditions: Bipolar I Depression
Interventions: RG2417, Placebo; Drug
Lead sponsor: Repligen Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 36
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 33 more

Conditions: Aging, Alzheimer Disease, Dementia Alzheimers, Dementia of Alzheimer Type, Fall Injury
Interventions: Novel Lighting Condition, Control Lighting Condition; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Interventions: Eplontersen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 46
States / cities: Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 35 more

Conditions: Periodontal Disease
Interventions: ST266, Saline (0.9% NaCl); Biological · Drug
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Cambridge, Massachusetts + 3 more

Conditions: Metastatic Melanoma
Interventions: MORAb-004 (monoclonal antibody); Biological
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 20
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 14 more

Conditions: Advanced Refractory Left Ventricular Heart Failure
Interventions: HeartMate 3 LVAS; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 69
States / cities: Little Rock, Arkansas • Beverly Hills, California • La Jolla, California + 53 more

Conditions: Ovarian Cancer
Interventions: carboplatin, paclitaxel; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 144
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 112 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Oral Budesonide Suspension (OBS), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 11 Years to 55 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 62
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Non-small Cell Lung Cancer
Interventions: communication intervention, Real Time Registry and data feedback only; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections, HIV Seronegativity
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 24 Hours to 21 Years
Enrollment: 4,150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2002
U.S. locations: 89
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more

Conditions: Neuroblastoma
Interventions: hu14.18-Interleukin-2 fusion protein; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 69
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more

Conditions: Contraception
Interventions: FemBloc® Permanent Contraceptive System; Device
Lead sponsor: Femasys Inc.; Industry
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 5
States / cities: Stamford, Connecticut • Miami, Florida • New York, New York + 2 more

Conditions: Ulcerative Colitis (UC)
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 8,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 170
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 133 more

Search by objective public record fields.

Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)

Digital Outreach Intervention for Lung Cancer Screening

19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

Precision Medicine and Physical Function

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia

Keep Social Study for Young Adults

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

The Nightlight Falls Prevention Study

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

MOMENTUM 3 Continued Access Protocol

Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer

An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)

Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention

Long-Term Effects of HIV Exposure and Infection in Children

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)